cho_logo_symbol_border

Clear Health Pass MDHeartPro

Save More Lives. Get to the Heart of Your Patient’s Risk with Clear Health Pass MDHeartPro.

Despite many recent advances in cardiovascular diagnosis and treatment, misdiagnosis is still a common concern for patients at risk of heart disease, the leading cause of death in the United States. As an advanced medical diagnostics facility, Premier Medical Laboratory Services developed Clear Health Pass MDHeartPro to detect cardiovascular disease early. Clear Health Pass MDHeartPro expands on the standard lipid panel by looking into more advanced biomarkers that gives the provider a more complete view of the patients’ cardiovascular health.

Are you seeing the full picture of patient risk?

Clear Health Pass MDHeartPro identifies more than 90% of people at risk for heart disease. Our series of new and commonly used tests provide a complete look at cardiovascular health. Measuring the patient’s total lipoprotein particle size, inflammatory markers (Hs-CRP, Lp-PLA2), genetic markers, metabolic syndrome, and the usual lipid panel. Clear Health Pass MDHeartPro can help doctor’s stop cardiovascular disease before it starts. 

50% of heart attacks occur in patients with normal cholesterol.

60% of patients who have a cardiac event have normal lipid levels.

30 Wall St. 8th floor New York, NY 10005

Clear Health Pass as Specifications Developer

Clear Health Pass Holdings, LLC  (“Clear Health Pass”) operates as a Specification Developer, developing specifications for devices distributed under its name, and is listed with the Food and Drug Administration. However, the Company does not engage in manufacturing activities.

Clear Health Pass Holdings, LLC  (“Clear Health Pass”) operates as a Specification Developer, developing specifications for devices distributed under its name, and is listed with the Food and Drug Administration. However, the Company does not engage in manufacturing activities.

As a Specification Developer, the Company may also arrange for the manufacturing of devices labeled with another establishment’s
name by a contract manufacturer.

The distribution of collection kits, specimen transport, marketing, test distribution, and actual testing is performed by a high-complexity Clinical Laboratory Improvement Amendments (CLIA) lab.

All testing conducted by the CLIA lab is compliant with the Centers for Medicare and Medicaid Services (CMS) CLIA Lab Amendments Act.

 

Our Journey to $1B+ Valuation

 

Disrupting Healthcare Testing / Diagnostics Early Detection of Cancer,
Chronic Conditions, Disease, Unlocking Anti-Aging Genomics & Promoting Longevity.

 

FUNDING GOAL $20,000,000

Funding Goal $20,000,000

20%

Skip to content